These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25069517)

  • 1. Deuterated drugs: where are we now?
    Timmins GS
    Expert Opin Ther Pat; 2014 Oct; 24(10):1067-75. PubMed ID: 25069517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deuterated drugs; updates and obviousness analysis.
    Timmins GS
    Expert Opin Ther Pat; 2017 Dec; 27(12):1353-1361. PubMed ID: 28885861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stable isotope biomarker breath tests for human metabolic and infectious diseases: a review of recent patent literature.
    Timmins GS
    Expert Opin Ther Pat; 2016 Dec; 26(12):1393-1398. PubMed ID: 27467014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deuterium isotope effects in drug pharmacokinetics II: Substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs.
    Sun H; Piotrowski DW; Orr STM; Warmus JS; Wolford AC; Coffey SB; Futatsugi K; Zhang Y; Vaz ADN
    PLoS One; 2018; 13(11):e0206279. PubMed ID: 30427871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals.
    Russak EM; Bednarczyk EM
    Ann Pharmacother; 2019 Feb; 53(2):211-216. PubMed ID: 30136594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoiding hindsight in non-obviousness determination: case law review of pharmaceutical patents and guidance from the KSR v Teleflex decision.
    Dhulap S; Kulkarni MG
    Expert Opin Ther Pat; 2021 Oct; 31(10):951-963. PubMed ID: 33993810
    [No Abstract]   [Full Text] [Related]  

  • 7. Deuterated driven new chemical entities: An optimistic way to improve therapeutic efficacy.
    Chandra Mouli HM; Vinod A; Kumari S; Tiwari AK; Kathiravan MK; Ravichandiran V; Peraman R
    Bioorg Chem; 2023 Jun; 135():106490. PubMed ID: 37001472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
    Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide.
    Jiang J; Pang X; Li L; Dai X; Diao X; Chen X; Zhong D; Wang Y; Chen Y
    Drug Des Devel Ther; 2016; 10():2181-91. PubMed ID: 27462143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The road more traveled--common pitfalls on the way to a patent.
    Tu S; Wu B; Maebius S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(1):1-4. PubMed ID: 20803518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Updates on the Development of Deuterium-Containing Drugs for the Treatment of Cancer.
    Belete TM
    Drug Des Devel Ther; 2022; 16():3465-3472. PubMed ID: 36217450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development.
    Harbeson SL; Morgan AJ; Liu JF; Aslanian AM; Nguyen S; Bridson GW; Brummel CL; Wu L; Tung RD; Pilja L; Braman V; Uttamsingh V
    J Pharmacol Exp Ther; 2017 Aug; 362(2):359-367. PubMed ID: 28611092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonium Salt Reagents for the Introduction of Deuterated Alkyl Groups in Drug Discovery.
    Ban K; Imai K; Oyama S; Tokunaga J; Ikeda Y; Uchiyama H; Kadota K; Tozuka Y; Akai S; Sawama Y
    Angew Chem Int Ed Engl; 2023 Nov; 62(48):e202311058. PubMed ID: 37726202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinetic isotope effect in the search for deuterated drugs.
    Shao L; Hewitt MC
    Drug News Perspect; 2010; 23(6):398-404. PubMed ID: 20697607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation patents and dermatology and obviousness.
    Mei DF; Liu J; Davitz MA
    Pharmaceutics; 2011 Nov; 3(4):914-22. PubMed ID: 24309313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonobviousness of pharmaceutical inventions: implications for patent prosecution and litigation.
    Dhulap S; Kulkarni M
    Pharm Pat Anal; 2019 Jul; 8(4):91-107. PubMed ID: 31414965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Application and Synthesis Methods of Deuterated Drugs.
    Xu XL; Zhang W; Rao GW
    Curr Med Chem; 2023; 30(36):4096-4129. PubMed ID: 36415097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for strengthening patent protection of pharmaceutical inventions in light of federal court decisions.
    Pillai X; Kinney WA
    Curr Top Med Chem; 2010; 10(18):1929-36. PubMed ID: 20615184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deuterium in drug discovery: progress, opportunities and challenges.
    Di Martino RMC; Maxwell BD; Pirali T
    Nat Rev Drug Discov; 2023 Jul; 22(7):562-584. PubMed ID: 37277503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.